Vorinostat (suberoylanilide hydroxamic acid, SAHA) is clinically active in advanced cutaneous T-cell lymphoma (CTCL): Results of a phase IIb trial.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Journal of Clinical Oncology

• Publication date

  2006-06-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2006.24.18_SUPPL.7500PMID 27955340
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• Relapsed/refractory mycosis fungoides and Sezary syndrome: biology, clinical manifestations and therapeutic options.

  2025cites this paper
• Immune pathways, current and potential therapies in Mycosis fungoides and Sezary syndrome

  2025cites this paper
• Management of Mycosis Fungoides and Sézary Syndrome With Oral Systemic Therapies

  2025cites this paper
• Repurposing Vorinostat for the Treatment of Disorders Affecting Brain

  2021cites this paper
• Mycosis fungoides and Sézary syndrome: Australian clinical practice statement

  2020cites this paper
• Assessment of Topical Therapies for Improving the Optical Clarity Following Stromal Wounding in a Novel Ex Vivo Canine Cornea Model.

  2018cites this paper
• The Legacy of Professor Ronald Charles D. Breslow

  2018cites this paper
• Targeted Therapies for the Treatment of Pediatric Non-Hodgkin Lymphomas: Present and Future

  2016cites this paper
• A phase 1 study of vorinostat maintenance after autologous transplant in high-risk lymphoma

  2015cites this paper
• Die Wirkung des Histondeacetylase-Inhibitors Valproinsäure auf Keimzelltumoren des Hodens

  2014cites this paper
• for refractory cutaneous T-cell lymphoma (CTCL) Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA)

  2013cites this paper
• Angiogenesis and antiangiogenic therapy in non-Hodgkin's lymphoma.

  2009cites this paper
• Molecular basis of the anti-cancer effects of histone deacetylase inhibitors.

  2009cites this paper
• Targeted therapies in B-cell non-Hodgkin lymphomas

  2009cites this paper
• Novel therapies for peripheral T-cell non-Hodgkin's lymphomas

  2009cites this paper
• Functional genetic screens as tools to discover signaling pathways targeted by cancer drugs

  2008cites this paper
• Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor-resistant acute myeloid leukemia cells.

  2008cites this paper
• Clinical Trials and Approved Drugs for Epigenetic Cancer Therapy

  2008cites this paper
• Emerging drugs for non-small-cell lung cancer

  2007cites this paper
• Systemic monotherapy vs combination therapy for CTCL: rationale and future strategies.

  2007cites this paper
• Phase I and Pharmacokinetic Study of Vorinostat, A Histone Deacetylase Inhibitor, in Combination with Carboplatin and Paclitaxel for Advanced Solid Malignancies

  2007cites this paper
• Rational Drug Design of Small Molecule Anticancer Agents: Early Clinical Development

  2007cites this paper
• Vorinostat in cutaneous T-cell lymphoma

  2007cites this paper
• Efficacy and tolerability of currently available therapies for the mycosis fungoides and Sezary syndrome variants of cutaneous T-cell lymphoma.

  2007cites this paper
• Discovery and development of SAHA as an anticancer agent

  2007cites this paper
• Histone Deacetylase Inhibitors: Biology and Mechanism of Action

  2007cites this paper
• Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma

  2007influential citation
• Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL).

  2007cites this paper
• HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics

  2007cites this paper
• Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug

  2007cites this paper
• Histone deacetylase inhibitors in cancer therapy

  2007cites this paper
• 42nd annual meeting of the American Society of Clinical Oncology June 2006, Atlanta, GA.

  2006cites this paper
• Mycosis fungoides and sezary syndrome: An update

  2006cites this paper
• Acetylation and Histone Deacetylase Inhibitors in Cancer

  2006cites this paper
• Primary cutaneous T-cell lymphomas.

  2006cites this paper
• Diagnosis and management of lymphoma.

  2006cites this paper
• A Phase II Study of Bortezomib in Relapsed/ Refractory Mantle Cell Lymphoma: PINNACLE Study

  2006cites this paper
• A series of novel, potent, and selective histone deacetylase inhibitors.

  2006cites this paper
• Individualizing therapy for the hematologic malignancies: the stuff of genes and dreams.

  2005cites this paper